A Multi-omics Approach to Disclose Progression and Underlying Biology of Head and Neck Adenoid Cystic Carcinoma
Studying Adenoid cystic carcinoma of the cervix uteri
Last synced from ClinicalTrials.gov
Key facts
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Principal Investigator
- Lisa LicitraFondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
- Intervention
- Standard of Care (Investigator Choice)(other)
- Enrollment
- 114 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2028
Study locations (1)
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Collaborators
Azienda Ospedaliera Brotzu · Istituto Oncologico Veneto I.O.V. - I.R.C.C.S. · Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale · Azienda Ospedaliero-Universitaria Maggiore della Carità di Novara · IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy · S. Orsola-Malpighi Hospital, University of Bologna
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07507578 on ClinicalTrials.govOther trials for Adenoid cystic carcinoma of the cervix uteri
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06781567Clinical Trial of HG146 Administered to Participants with Adenoid Cystic CarcinomaHitGen Inc.
- ACTIVE NOT RECRUITINGPHASE2NCT04209660Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland CancersMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE2NCT04214366Adenoid Cystic Carcinoma and Carbon Ion Only IrradiationHeidelberg University
- RECRUITINGPHASE1, PHASE2NCT03556228VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or LymphomaVM Oncology, LLC
See all trials for Adenoid cystic carcinoma of the cervix uteri →